Investment Thesis
aTYR Pharma faces critical financial distress with revenue of only $190K against $12.5M annual operating cash burn, leaving less than one year of cash runway. The company exhibits the financial profile of an early-stage biotech with zero commercial traction, declining revenue (-19.1% YoY), and structurally unsustainable operations requiring immediate external funding or strategic pivot.
Strengths
- Minimal debt burden with 0.05x debt-to-equity ratio
- Positive stockholders' equity of $57.9M provides balance sheet foundation
- Strong current ratio of 5.78x indicates technical liquidity despite operational distress
Risks
- Critical cash runway of approximately 10 months at current $12.5M annual burn rate with only $10M liquid reserves
- Negligible revenue of $190K against massive operating losses of $11.4M indicates zero commercial viability
- Declining year-over-year revenue trend (-19.1%) suggests deteriorating business momentum without offsetting cost reduction
Key Metrics to Watch
- Cash position and runway - critical threshold for survival
- Operating cash burn rate - trend toward sustainability or accelerating deterioration
- Revenue inflection - any meaningful commercial progress or clinical milestone funding
Financial Metrics
Revenue
190.0K
Net Income
-10.8M
EPS (Diluted)
$-0.11
Free Cash Flow
-12.7M
Total Assets
79.7M
Cash
10.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-6,018.9%
Net Margin
-5,679.5%
ROE
-18.6%
ROA
-13.5%
FCF Margin
-6,660.5%
Balance Sheet & Liquidity
Current Ratio
5.78x
Quick Ratio
5.78x
Debt/Equity
0.05x
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
2.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T07:00:03.242975 |
Data as of: 2026-03-31 |
Powered by Claude AI